re: can you paste the relevance to csl sorry have to do own...

re: can you paste the relevance to csl sorry have to do own research,heres some for you.

PRINCIPAL ACTIVITY
CSL Limited (CSL) specialises in biologically-based health care products. The
company's main operations are in the manufacture and supply of blood
products and vaccines.

BIOPLASMA: CSL's involved in the sourcing, fractionating, testing and supplying
of human plasma-derived products worldwide. The division consists of ZLB
Bioplasma< ZLB Plasma Services and CSL Bioplasma businesses which operate in
the US, Australia, Asia and Europe. CSL has major contracts are with the
Australian and American Red Cross.

PHARMACEUTICALS: Develops, manufactures and markets vaccines and pharmaceutical
products for human use as well as marketing vaccines, antibiotics and other
prescription pharmaceutical products in Australia and NZ for international
partners. One of the company's main products is an influenza vaccine called
Fluvax which is also sold in the Northern Hemisphere.

JRH BIOSCIENCES GROUP: Develops, manufactures and markets cell culture
reagents, blood grouping reagents, research immunohematology and human
diagnostics. Includes the American, European and Australian-based
operations. Agreement with GroPep Ltd (Aust) for marketing rights to a range
of fecombiant growth factors. A large proportion of the division's revenue
is derived from North America, Europe and Japan.

VETERINARY: Develops, manufactures and markets vaccines for farm livestock and
pets with production facilities in Australia, New Zealand and the USA. CSL
currently has products for; cats, cattle, dogs, goats, horses, pigs, sheep
and animal anti-venoms. CSL also produces a range of animal diagnostic
products.

RESEARCH AND DEVELOPMENT: Research and development is a significant part of
CSL's operations. Well established R&D groups exist in all 4 businesses. In
November 2002, CSL announced that Phase III clinical trials of the Human
Papilloma virus (HPV) vaccine had shown that the vaccine demonstrated 100%
protection against HPV 16, one type of HPV commonly associated with cervical
cancer. HPV plays an important role in causing around 470,000 cases of
cervical cancer worldwide per annum.

STRATEGY ANALYSIS & PROFIT REPORT
Falling IVIG prices have been mostly responsible for CSL's deteriorating share
price over the last year. Recently, the share price has bounced back
slightly with the announcement that cervical cancer vaccine tests by Merck &
Co Inc using CSL technology have had positive results. A proof-of-principle
study demonstrated 100% protection against human papillomavirus (HPV) 16
which is one type of HPV associated with cervical cancer. In addition to
royalties, CSL has the exclusive right to market any Merck HPV vaccine in
Australia and New Zealand.

CSL posted a strong lift in NPAT to $124m, representing a 58% on the pcp. The
result was driven by similar growth in group revenues, which included for
the first time $282m from its new Plasma Services division. Despite a 2%
drop in sales from the Animal Health division, EBIT grew by 107% to $4m.
Biosciences also had a spectacular performance with EBIT increasing by 83%
on the back of a 34% lift in sales.

In a move to expand the company's access to plasma in the US market, CSL has
acquired 47 US based plasma collection centres and associated laboratory
facilities. The deal, valued at US$152 million, secures the company's plasma
supplies which are necessary for continued growth from ZLB. This follows the
$1 billion acquisition of the plasma products division of the Swiss Red
Cross, ZLB completed in September 2000. ZLB's products are sold in over 20
country's worldwide including the US and Europe.